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A B S T R A C TObjectives: As a nation with a developing economy, Croatia is faced
with making choices between pharmaceutical products, including
depot injectable antipsychotics. We conducted a pharmacoeconomic
analysis to determine the cost-effectiveness of atypical depots in
Croatia. Methods: A 1-year decision-analytic framework modeled
drug use. We determined the average direct cost to the Croatian
Institute for Health Insurance of using depot formulations of paliper-
idone palmitate long-acting injectable (PP-LAI), risperidone LAI (RIS-
LAI), or olanzapine LAI (OLZ-LAI). An expert panel plus literature-
derived clinical rates populated the core model, along with costs
adjusted to 2012 by using the Croatian consumer price index. Clinical
outcomes included quality-adjusted life-years, hospitalization rates,
emergency room treatment rates, and relapse days. Robustness of
results was examined with one-way sensitivity analyses on important
inputs; overall, all inputs were varied over 10,000 simulations in a
Monte Carlo analysis. Results: Costs (quality-adjusted life-years) per
patient were €5061 (0.817) for PP-LAI, €5168 (0.807) for RIS-LAI, andsee front matter Copyright & 2013, International S
r Inc.
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a M5V 3M8.€6410 (0.812) for OLZ-LAI. PP-LAI had the fewest relapse days,
emergency room visits, and hospitalizations. Results were sensitive
against RIS-LAI with respect to drug costs and adherence rates, but
were generally robust overall, dominating OLZ-LAI in 77.3% and RIS-
LAI in 56.8% of the simulations. Conclusions: PP-LAI dominated the
other drugs because it had the lowest cost and best clinical outcomes.
Compared with depots of olanzapine and risperidone and oral
olanzapine, PP-LAI was the cost-effective atypical LAI for treating
chronic schizophrenia in Croatia. Using depot paliperidone in place of
either olanzapine or risperidone would reduce the overall costs of
caring for these patients.
Keywords: Croatia, long-acting injectable, paliperidone palmitate,
pharmacoeconomic analysis, risperidone, schizophrenia.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Croatia is a country with a developing economy whose health care
system has been developing over some time [1,2]. The Croatian
Institute for Health Insurance [3] was established in 1993 to manage
the health system that is provided for all citizens. This system is
based on a national health insurance model, with compulsory
contributions for all employed persons and employers, with co-
payments for drugs and services. Noninsured services are paid either
out of pocket or through additional voluntary health insurance.
In 1998, a law was passed that guaranteed treatment and also
safeguarded the personal rights for persons with schizophrenia
requiring involuntary hospitalization [4,5]. Since that time, there
has been an increase in both the availability and use of anti-
psychotics [6,7]. Utilization patterns have changed, with a shift
from the older, less expensive ﬁrst-generation drugs to newer
and more costly atypical antipsychotics [6–10].Problems in drug use, especially nonadherence and polyphar-
macy, have exacerbated the situation [11,12]. As a result, there
have been increasing numbers of hospitalizations [13]. Harvey
et al. [14] noted that hospitalization consumed the largest
proportion of total health care costs (430%) in Croatia. In
addition, the plan to reintegrate persons with schizophrenia into
the community has not been entirely successful [15]. All these
factors have served to increase costs for the health system;
however, its ﬁnancial resources are insufﬁcient to cover all the
demands. Therefore, cost-effective approaches are needed to
maintain and improve the treatment of persons with chronic
schizophrenia.
In 2002, the Croatian Institute for Health Insurance funded a
project to address rational drug use [14]. A main component was
determining how savings could be made by incorporating phar-
macoeconomic principles into the selection and purchase of
drugs on the Croatian formulary. They observed that “there wasociety for Pharmacoeconomics and Outcomes Research (ISPOR).
o conﬂicts of interest with regard to the content of this article.
of Pharmacy, 144 College Street, Room 674, University of Toronto,
Fig. 1 – Model used for the pharmacoeconomic analysis. LAI, long-acting injectable; OLZ-LAI, olanzapine pamoate long-acting
injectable; PP-LAI, paliperidone palmitate long-acting injectable.
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ment appropriate to the Croatian economic situation.” This
observation highlights the need for evidence-based information
on the cost-effectiveness of psychopharmaceuticals.
At the same time, the rights and dignity of these people must
be respected. Two critical aspects are image [16] and quality of
life [17,18]. Nawková et al. [19] assessed articles in the lay press in
Croatia describing mental health and found that 40 out of the 75
(53%) articles portrayed a negative image. Mentally ill persons
were mostly presented as dangerous and involved in aggressive
crimes such as homicide (49%) or physical assaults (31%). Martić-
Biocina and Barić [12] also identiﬁed dissatisfaction with the role
of the media in that respect. They also found a high level of
stigma toward people with schizophrenia and that it correlated
with medication nonadherence and hospitalizations. The same
was found with quality-of-life issues [18]. These authors also
reported that the atypical antipsychotics were superior to tradi-
tional drugs with respect to increasing quality of life in persons
with chronic schizophrenia. Jukić et al. [20] suggested that their
side-effect proﬁle may be responsible for improved quality of life.
Depot forms of antipsychotic drugs were developed to at least
partially address issues of nonadherence [21]. In the past decade,
long-acting injectable (LAI) formulations of atypical agents have
been marketed to ﬁll a perceived need. Risperidone LAI (RIS-LAI)
was the ﬁrst such drug [22], and has recently been joined
by olanzapine LAI (OLZ-LAI) [23] and paliperidone LAI (PP-LAI)
[24]. In another country undergoing economic change, apharmacoeconomic analysis found that PP-LAI was cost-
effective when compared with RIS-LAI [25]. It is not currently
known whether the outcomes would be similar in this country.
We therefore undertook this research to assess the cost-utility of
PP-LAI compared with other LAIs in Croatia from the point of
view of the Croatian Institute for Health Insurance.Methods
Target Population
We examined the use of atypical LAIs in persons with stable
chronic schizophrenia but who had a history of relapses and
hospitalizations. They have been referred to as “revolving door”
patients who are difﬁcult to treat and have problems with
adherence to prescribed medications [26,27]. Consequently, they
impose a very large burden on health care resources.
Drugs Analyzed
The drug of primary interest was PP-LAI. Comparison drugs
included the other atypical depots (i.e., RIS-LAI and OLZ-LAI).
According to the product summaries of the European Medicines
Agency, PP-LAI (Xeplion) can be dosed monthly [28], OLZ-LAI
(Zypadhera) is administered every 2 or 4 weeks [29], and RIS-LAI
(Risperdal Consta) requires biweekly injections [30].
Table 1 – Clinical inputs into the model.
LAI
antipsychotic
Clinical input
(amount/rate)
Rate Source
Olanzapine Dose to
initialize
therapy
300 mg q2 weeks  3
injections
European Medicines Agency [29]
Maintenance
dose
432 mg q4 weeks Kane et al. [34]
Dose for acute
relapse
473 mg q4 weeks Lauriello et al. [35]
Adherence 0.803 Ascher-Svanum et al. [36]
Stable disease 0.793 Kane et al. [34]
ER visits 0.062 Kane et al. [34]
Hospitalization
rate
0.145 Calculation [1 – rates of (ER visits þ stable disease)]
Paliperidone Dose to
initialize
therapy
150 mg week 1, 100 mg
week 2, then 82.8 mg
every 4 wk
European Medicines Agency [28], Hough et al. [37]
Maintenance
dose
69.3 mg monthly Average from Gopal et al. [38] and Fleischhacker et al. [39]
Dose for acute
relapse
84.9 mg monthly Gopal et al. [40], Pandina et al. [41], Hough et al. [42], Nasrallah et al.
[43], Pandina et al. [44]
Adherence 0.872 RIS-LAI rate from Olivares et al. [45] adjusted via Mehnert and Diels
[46]
Stable disease 0.803 Calculation [1 – rates of (ER visits þ hospitalization)]
ER visits 0.059 Hospital rate  ER:hospital ratio from Ascher-Svanum et al. [36]
Hospitalization
rate
0.138 Hough et al. [37], Gopal et al. [38]
Risperidone Maintenance
dose
40.3 mg biweekly Fleischhacker et al. [39], Kissling et al. [47], Lee et al. [48],
Lindenmayer et al. [49], Olivares et al. [50]
Dose for acute
relapse
50 mg biweekly Prorated from PP-LAI dose; similar to doses used by Kane et al. [22],
Chue et al. [51], Eerdekens et al. [52] who used 58 mg, but 50 mg is
the maximum allowable dose [30]
Adherence 0.823 Olivares et al. [45]
Stable disease 0.763 Calculation [1 – rates of (ER visits þ hospitalization)]
ER visits 0.071 Hospital rate  ER:hospital ratio from Ascher-Svanum et al. [36]
Hospitalization
rate
0.166 Olivares et al. [50], Weiden and Olfson [53]
ER, emergency room; LAI, long-acting injectable; PP, paliperidone palmitate; RIS, risperidone microspheres.
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We adapted a previously validated decision tree [25] for use in
Croatia, using input from clinical and administrative experts.
Figure 1 depicts the model. To begin the analysis, we start withTable 2 – Cost inputs (2012€).
Resource Item Uni
Drugs Olanzapine depot mg
Risperidone depot mg
Paliperidone depot mg
Olanzapine tablets mg
Risperidone tablets mg
Clozapine tablets mg
Medical Primary care physician 1 vis
Psychiatrist outpatient visit 1 vis
Psychiatric nurse 1 h
Hospital Emergency room 1 vis
Hospital bed acute care 1 d
Hospital long-term bed 1 d
Day care visit 1 dan average patient having chronic relapsing schizophrenia but
whose disease is currently stabilized. Because of adherence
problems, patients are maintained on standard doses of depot
antipsychotics. They may be either adherent or nonadherent, ast Cost (€) Source
3.50 Croatian Ofﬁcial Gazette [58]
3.50 Croatian Ofﬁcial Gazette [58]
3.76 Croatian Ofﬁcial Gazette [58]
0.21 Croatian Ofﬁcial Gazette [58]
0.20 Croatian Ofﬁcial Gazette [58]
0.0036 Croatian Ofﬁcial Gazette [58]
it 16.62 Local medical price list
it 14.10 Vrapče hospital price list
7.45 Vrapče hospital price list
it 230.32 Vrapče hospital price list
96.81 Vrapče hospital price list
33.51 Vrapče hospital price list
26.20 Vrapče hospital price list
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V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 1 8 1 – 1 8 8184per published rates and expert opinion. Some will continue in the
stable state, while the rest will relapse. All relapsers would be
seen at the emergency room, and the more severe cases would be
admitted to the acute psychiatric unit. Those unable or unwilling
to tolerate the initial treatment would be switched. Those
discontinuing PP-LAI or RIS-LAI would then receive OLZ-LAI,
and those switching from OLZ-LAI would receive PP-LAI; dis-
continuers of oral OLZ would receive RIS-LAI. Patients who failed
two different drugs would be given clozapine, in accordance with
National Institute for Health and Clinical Excellence guidelines
[31] and local practice using doses reported in the literature
[32,33].
Clinical Inputs
Table 1 lists the clinical inputs used in this mode, by drug, as
well as the sources of information [22,28–30,34–53]. The doses
of drugs used were derived from randomized clinical trials
and long-term studies published in the literature. Where data
were presented for nonadherent patients, we extracted rates
from the published articles. In other cases, we used either
the rates for placebo in trials (e.g., PP-LAI; OLZ-LAI assumed
equal) or we calculated rates by using the ratio of adherent:
nonadherent patients from Weiden and Olfson [53] (e.g., RIS-
LAI).
With each drug, adjunct therapy was added, in accordance
with typical clinical trials. Gopal et al. [38] indicated that PP-LAI
was augmented with oral risperidone in a dose of 6.8 mg/d for
30.5 days. In a similar trial, Möller et al. [54] reported that 22%
of the patients receiving RIS-LAI required oral supplementation
with 3.2 mg/d for 43 days. Ascher-Svanum et al. [55] noted
that OLZ-LAI required 10.8 mg/d for 31 days in 21% of the
patients.
Some economic analyses have used standard doses such as
deﬁned daily doses (DDDs) [56]; however, DDDs reﬂect the
average dose when used for the most common indication. It
should be remembered that we are dealing with revolving door
patients who comprise only a subset of patients who represent
the extreme of the spectrum. Thus, we feel that DDDs would
underestimate the doses used in actual practice when managing
such problematic patients.
In calculating adherence rates, we used experience from large
observational studies. The rate for RIS-LAI was taken from a large
patient registry (n ¼ 1648) of patients with longstanding schizo-
phrenia [45]. Because there was insufﬁcient long-term experience
with PP-LAI, that rate was adjusted by using results from the
study by Mehnert and Diels [46]. They compared adherence
between RIS-LAI when administered monthly and twice weekly,
ﬁnding a minimum of 5.1% increase in adherence with monthly
injections. That factor was applied to PP-LAI, which is adminis-
tered monthly and is a metabolite of RIS-LAI, thereby having the
same adverse-event proﬁle. For OLZ-LAI, we used the rate from a
large cohort (n ¼ 1906). Even though that rate was with oral drugs
(which normally have lower adherence rates than do depots), we
used that value of 80.2% because it was higher than the 72.7%
rate in 931 patients found with the depot form by Ascher-
Svanum et al. [57], and was quite similar to the rates of other
depot atypicals.
Cost Inputs
We considered all direct costs from the viewpoint of the National
Health Service of Croatia, as presented in Table 2 [58] (local
medical price list and Vrapče hospital price list). We did not
include indirect costs such as time lost from work, because
very few of these people participate fully in the workforce.
A multicountry study in Europe reported that less than 10% of
Fig. 2 – Cloud diagram from the probabilistic sensitivity analysis comparing incremental costs (Y axis) and QALYs (X axis)
between (A) PP-LAI and RIS-LAI and (B) PP-LAI and OLZ-LAI. OLZ-LAI, olanzapine pamoate long-acting injectable; PP-LAI,
paliperidone palmitate long-acting injectable; QALY, quality-adjusted life-year; RIS-LAI, risperidone long-acting injectable.
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another 12.3% worked part-time [59]. We did not apply discount-
ing because the analytic time horizon was 1 year. Prices
were taken from current lists or from the literature, and then
inﬂated to 2011 euros by using the consumer price index for
Croatia [60].
Utilities
Utilities for the analysis were obtained from the literature;
values obtained were simply averaged [61–65]. Stable disease
had a utility of 0.890; an exacerbation requiring outpatient
treatment at the hospital emergency room had a utility of
0.659 for emergency room exacerbation and 0.490 for
hospitalization.Analysis and Outputs
No ofﬁcial guidelines currently exist for pharmacoeconomic
analyses in Croatia. We therefore used a standard approach that
had been used in previous analyses in Europe [25]. The decision
tree produced expected outcomes for the average patient treated
with average doses of each drug. These outcomes included the
cost per patient treated, measured in 2012 euros, as well as
numbers of hospitalizations, emergency room visits, days with
stable disease, and quality-adjusted life-years (QALYs) for each
drug. The economic outcome of prime interest was the incre-
mental cost per QALY.
We explored the effect of variations in input values on out-
puts by applying one-way sensitivity analyses on all important
inputs such as costs and clinical rates. Break-even analysis
identiﬁed the points where outcomes changed qualitatively. We
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10,000 Monte Carlo simulations on all inputs and standard
distributions (i.e., beta for rates and gamma for costs) [66].
Proportions of incremental cost-effectiveness ratios falling into
each of the four major quadrants (cost vs. QALYs) were calculated
and compared.Results
Results of the base-case analysis appear in Table 3. PP-LAI had
the lowest overall cost to treat one patient for 1 year (€5061),
followed by RIS-LAI (€5168), with OLZ-LAI costing the most
(€6410). Clinical outcomes were also better in all cases for PP-
LAI; it had the most days in remission and the fewest hospital-
izations and emergency room visits. Also, it was associated
with the highest QALY score, but differences for this outcome
were not large. Because its cost was lowest and QALYs (and
other beneﬁcial clinical outcomes) highest, it dominated the
other drugs. That is, it should be considered the preferred
choice.
In one-way sensitivity analyses, PP-LAI was not sensitive to
changes in cost relative to OLZ-LAI. Its cost would need to
increase 64% or that of OLZ-LAI decrease by 54% to lose its
dominance. However, it would not dominate RIS-LAI with a 4%
increase in the cost of PP-LAI or a 4.4% decrease in the cost of RIS-
LAI. If the unit cost of PP-LAI were equal to that of RIS-LAI, the
expected cost/patient would decline to €4756. Results were
sensitive to reasonable changes in adherence rate (10% for
OLZ-LAI and 18% for RIS-LAI). Hospitalization rates were not
sensitive.
Figure 2A,B depicts results from the probabilistic sensitivity
analyses. PP-LAI dominated OLZ-LAI in about 77.3% of the
simulations and RIS-LAI in 56.8% of the simulations. It was
cost-effective (i.e., incremental cost-effectiveness ratios o
€30,000) compared with RIS-LAI in another 37% of the trials
(overall 93%). However, PP-LAI was dominated in 1.3% of the
20,000 iterations, in total.Discussion
A search of the literature could ﬁnd no examples of pharmacoe-
conomic analyses that examined the pharmacotherapy of schiz-
ophrenia in Croatia. Therefore, we believe that this is the ﬁrst
such analysis. Because decision makers and health care providers
are being faced with increasing demands from patients and their
advocates without a corresponding increase in revenues, they
must take advantage of these quantitative approaches to aid in
selecting what to fund. Relying solely on acquisition prices of
drugs, services, or other products can be misleading because all
factors impacting the choice are not being considered. Because of
enhanced efﬁcacy, a drug with a higher price may be the best
choice if it prevents the consumption of other resources, such as
hospitalization.
In this analysis, PP-LAI dominated the other available atypical
LAIs. Results could change against RIS-LAI with changes in cost
or against OLZ-LAI with changes in adherence. The overall
probabilistic sensitivity analyses, however, did indicate that PP-
LAI would be the drug of choice in the majority of cases.
In addition to the clinical and economic advantages, there is
an advantage for PP-LAI with respect to convenience. This drug
may be administered monthly, while its nearest competitor, RIS-
LAI, must be given every 2 weeks. Monthly dosing would seem to
be the preferable situation for both the patient and the busy
practitioner.This analysis has some limitations, which should be noted.
Rates of adherence and hospitalization were taken from the
literature and were assumed to apply as well in this country.
We considered only persons with chronic schizophrenia in a
stable state. Those who are hospitalized or experiencing an acute
exacerbation of symptoms would require more aggressive treat-
ment; therefore, costs and outcomes might vary.
We did not consider the treatment of adverse events other
than postinjection syndrome in this analysis for a number of
reasons. First, these events are quite common in all antipsychotic
drugs. Many of these problems can be managed by reducing the
dose or changing to another drug. Also, these patients are
required to visit their physician or other practitioner (e.g.,
psychiatric nurse or psychologist) on a regular basis, and so they
would not likely incur extra visits because of adverse events. In
addition, many require treatment with drugs (e.g., anticholiner-
gics) that are very inexpensive and add little to the overall cost of
care, especially on a comparative basis. Finally, reports from
ofﬁcial agencies have concluded that adverse events associated
with these drugs have little appreciable impact overall [67,68].Conclusions
In this analysis, we found that PP-LAI was the dominant choice
for treating chronic relapsing schizophrenia in Croatia. Its higher
acquisition cost was more than offset by reductions in other
health care areas, such as decreased hospitalizations, visits to
emergency room, and visits to other health care practitioners.
Results were sensitive to minor changes in adherence rates.
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